PT1718340E - Novos conjugados de efectores, processo para a sua produção e sua utilização farmacêutica - Google Patents

Novos conjugados de efectores, processo para a sua produção e sua utilização farmacêutica Download PDF

Info

Publication number
PT1718340E
PT1718340E PT05707090T PT05707090T PT1718340E PT 1718340 E PT1718340 E PT 1718340E PT 05707090 T PT05707090 T PT 05707090T PT 05707090 T PT05707090 T PT 05707090T PT 1718340 E PT1718340 E PT 1718340E
Authority
PT
Portugal
Prior art keywords
production
pharmaceutical use
new effector
effector conjugates
conjugates
Prior art date
Application number
PT05707090T
Other languages
English (en)
Inventor
Ulrich Klar
Andreas Menrad
Joerg Willuda
Klaus Bosslet
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004004787A external-priority patent/DE102004004787A1/de
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PT1718340E publication Critical patent/PT1718340E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT05707090T 2004-01-30 2005-01-31 Novos conjugados de efectores, processo para a sua produção e sua utilização farmacêutica PT1718340E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53997704P 2004-01-30 2004-01-30
DE102004004787A DE102004004787A1 (de) 2004-01-30 2004-01-30 Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung

Publications (1)

Publication Number Publication Date
PT1718340E true PT1718340E (pt) 2008-02-07

Family

ID=34839581

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05707090T PT1718340E (pt) 2004-01-30 2005-01-31 Novos conjugados de efectores, processo para a sua produção e sua utilização farmacêutica

Country Status (10)

Country Link
EP (1) EP1718340B1 (pt)
JP (1) JP2007519681A (pt)
CY (1) CY1107207T1 (pt)
DE (1) DE602005003453T2 (pt)
DK (1) DK1718340T3 (pt)
ES (1) ES2296133T3 (pt)
PL (1) PL1718340T3 (pt)
PT (1) PT1718340E (pt)
SI (1) SI1718340T1 (pt)
WO (1) WO2005074901A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
PE20080316A1 (es) 2006-05-25 2008-04-10 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
EP2481427A1 (en) 2007-03-14 2012-08-01 Endocyte, Inc. Folate-Tubulysin conjugates
WO2008147941A1 (en) 2007-05-25 2008-12-04 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
US20100178293A1 (en) * 2007-06-22 2010-07-15 Olaf Weber Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006505627A (ja) * 2002-07-31 2006-02-16 シエーリング アクチエンゲゼルシャフト 新規エフェクター接合体、それらの生成方法及びそれらの医薬使用
DE10305098A1 (de) * 2003-02-07 2004-08-19 Schering Ag Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
DE10234975A1 (de) * 2002-07-31 2004-02-12 Schering Ag Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
EP1581218A1 (en) * 2002-12-05 2005-10-05 Schering AG Epothilone analogs for site specific delivery in the treatment of proliferative diseases
DE10256982A1 (de) * 2002-12-05 2004-06-24 Schering Ag Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung

Also Published As

Publication number Publication date
DE602005003453D1 (de) 2008-01-03
CY1107207T1 (el) 2012-11-21
EP1718340B1 (en) 2007-11-21
WO2005074901A3 (en) 2006-03-30
EP1718340A2 (en) 2006-11-08
JP2007519681A (ja) 2007-07-19
DK1718340T3 (da) 2008-03-03
SI1718340T1 (sl) 2008-04-30
PL1718340T3 (pl) 2008-04-30
ES2296133T3 (es) 2008-04-16
WO2005074901A2 (en) 2005-08-18
DE602005003453T2 (de) 2008-09-25

Similar Documents

Publication Publication Date Title
SI1718340T1 (sl) Novi efektorski konjugati, postopek za njihovo proizvodnjo in njihova farmacevtska uporaba
IL176913A0 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
IL181012A0 (en) Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments
PL1928882T3 (pl) (S)-N-Metylonaltrekson, sposoby jego syntezy i jego zastosowania farmaceutyczne
PL378065A1 (pl) Podstawione związki N-aryloheterocykliczne, sposób ich wytwarzania oraz ich zastosowanie jako środków leczniczych
IL185804A0 (en) Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
IL184175A0 (en) Sulfonyl pyrrolidines, method for producing the same and their use as drugs
PL374528A1 (en) New effector conjugates, process for their production and their pharmaceutical use
IL228730A (en) Pharmaceutical manufacturing process
IL179170A0 (en) Novel substituted thiophenecarboxamides, their production and their use as medicaments
EP1731139A4 (en) PHARMACEUTICAL PREPARATION OF THE S / O TYPE AND MANUFACTURING METHOD THEREFOR
TWI315305B (en) Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof
IL193339A0 (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IL193341A0 (en) Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
EP2025672A4 (en) 7-ELEMENT HETEROCYCLIC RING, PROCESS FOR PRODUCTION THEREOF AND PHARMACEUTICAL USES THEREOF
SI2020410T1 (sl) Derivati pirido(2,3-d)pirimidina, njihova priprava, njihova terapevtska uporaba
HUP0500921A2 (en) Tetrazole derivatives, process for their preparation and their use
PL377741A1 (pl) Pochodne diarylocykloalkilowe, sposób ich wytwarzania i ich zastosowanie jako środka leczniczego
IL186862A0 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
EP2025667A4 (en) 9, 10-SECOPREGNANDERIVAT AND MEDICINAL PRODUCTS
IL190596A0 (en) 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
ZA200805382B (en) Keratin-binding effector molecules, and method for the production thereof
HK1100424A1 (en) Oral preparations and process for production thereof
ZA200710146B (en) New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
HK1100946A1 (en) 1-a-HALO-2,2-DIFLUORO-2-DEOXY-D-RIBOFURANOSE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF